Refine
Year of publication
Has Fulltext
- yes (64)
Is part of the Bibliography
- no (64) (remove)
Keywords
- TAVI (5)
- alirocumab (4)
- Aortic stenosis (3)
- Inflammation (3)
- acute coronary syndrome (3)
- biomarker (3)
- Cardiovascular biology (2)
- MitraClip (2)
- aortic valve stenosis (2)
- 16 segment AHA model (1)
- Acute coronary syndrome (1)
- Akutes Koronarsyndrom (1)
- Alcohol consumption (1)
- Aortic stiffness (1)
- Atrial fibrillation (1)
- Balloon-expandable TAVI (1)
- Biomarkers (1)
- Blood pressure (1)
- COVID 19 (1)
- COVID-19 (1)
- Cardiac troponin (1)
- Cardiovascular disease risk (1)
- Cardiovascular diseases (1)
- Cardiovascular magnetic resonance (1)
- Cholesterin (1)
- Chronic heart failure (1)
- Chronic kidney disease (1)
- Coagulation (1)
- Combo® DTS (1)
- Coronary artery disease (1)
- Decision making (1)
- Depression (1)
- Diagnostic markers (1)
- EQ5D5L (1)
- ER stress (1)
- Emotions (1)
- Endothelial cells (1)
- Fibroblast growth factor (1)
- Functional mitral regurgitation (1)
- Heart failure (1)
- Hemodynamics (1)
- Hypertension (1)
- KCCQ (1)
- Kidney transplant recipients (1)
- MAGGIC score (1)
- Mental health and psychiatry (1)
- Molecular biology (1)
- Monocytes (1)
- Mortality (1)
- Multivariate analysis (1)
- Myocardial infarction (1)
- Myocardial injury (1)
- Myocardial perfusion (1)
- Myocardial revascularization (1)
- Myocardial segmentation (1)
- NIRS (1)
- Native T1 mapping (1)
- Observational studies (1)
- Outcome (1)
- PCSK9 protein (1)
- PV loop (1)
- Percutaneous coronary intervention (1)
- Prognostic markers (1)
- Pulmonary artery pressure (1)
- Remote monitoring (1)
- Risk prediction (1)
- SARS CoV 2 (1)
- SARS-CoV-2 (1)
- Seattle heart failure model (1)
- Self-expandable TAVI (1)
- Sterblichkeit (1)
- Stroke (1)
- Sub-segmentation (1)
- T cells (1)
- TAPSE (1)
- Testosterone (1)
- Virus trapping (1)
- acute coronary syndromes (1)
- age (1)
- ageing (1)
- anemia (1)
- aortic stenosis (1)
- biomarkers (1)
- blood cell mutations (1)
- cardiac (1)
- cardiac magnetic resonance (1)
- cardiovascular (1)
- cerebrovascular disease (1)
- cholesterol (1)
- chronic kidney disease (1)
- chronic total occlusion (1)
- clonal haematopoiesis (1)
- cohort study (1)
- death (1)
- decision aids (1)
- delirium (1)
- endothelial (1)
- epigenetics (1)
- erythropoietin (EPO) (1)
- heart failure (1)
- low-density lipoprotein cholesterol (1)
- major adverse cardiac events (1)
- major adverse cardiovascular events (1)
- miRNAs (1)
- mitral regurgitation (1)
- mitral valve surgery (1)
- mortality (1)
- musclin (1)
- myocardial fibrosis (1)
- non-ST-segment elevation acute coronary syndrome (1)
- optical coherence tomography (1)
- outcomes (1)
- oxidative stress (1)
- peripheral artery disease (1)
- personalized (1)
- prediction (1)
- prognostic value (1)
- proprotein convertase subtilisin/kexin type 9 inhibition (1)
- scar (1)
- sleep disordered breathing (1)
- stroke (1)
- total events (1)
- transcatheter aortic valve replacement (TAVR), aortic valve stenosis (AS) (1)
Institute
Cathepsin D (CatD) is a lysosomal aspartic proteinase and plays an important role in the degradation of proteins and in apoptotic processes induced by oxidative stress, cytokines, and aging. All of these stimuli are potent inducers of endothelial cell apoptosis. Therefore, we investigated the role of CatD in endothelial cell apoptosis and determined the underlying mechanisms. Incubation with 100-500 microm H2O2 for 12 h induced apoptosis in endothelial cells. To determine a role for CatD, we co-incubated endothelial cells with the CatD inhibitor pepstatin A. Pepstatin A as well as genetic knock down of CatD abolished H2O2-induced apoptosis. In contrast, overexpression of CatD wild type but not a catalytically inactive mutant of CatD (CatDD295N) induced apoptosis under basal conditions. To gain insights into the underlying mechanisms, we investigated the effect of CatD on reactive oxygen species (ROS) formation. Indeed, knocking down CatD expression reduced H2O2-induced ROS formation and apoptosis. The major redox regulator in endothelial cells is thioredoxin-1 (Trx), which plays a crucial role in apoptosis inhibition. Thus, we hypothesized that CatD may alter Trx protein levels and thereby promote formation of ROS and apoptosis. Incubation with 100 microm H2O2 for 6 h decreased Trx protein levels, whereas Trx mRNA was not altered. H2O2-induced Trx degradation was inhibited by pepstatin A and genetic knock down of CatD but not by other protease inhibitors. Incubation of unstimulated cell lysates with recombinant CatD significantly reduced Trx protein levels in vitro, which was completely blocked by pepstatin A pre-incubation. Overexpression of CatD reduced Trx protein in cells. Moreover, H2O2 incubation led to a translocation of Trx to the lysosomes prior to the induction of apoptosis. Taken together, CatD induces apoptosis via degradation of Trx protein, which is an essential anti-apoptotic and reactive oxygen species scavenging protein in endothelial cells.
α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis
(2018)
Metastasis formation requires active energy production and is regulated at multiple levels by mitochondrial metabolism. The hyperactive metabolism of cancer cells supports their extreme adaptability and plasticity and facilitates resistance to common anticancer therapies. In spite the potential relevance of a metastasis metabolic control therapy, so far, limited experience is available in this direction. Here, we evaluated the effect of the recently described α-ketoglutarate dehydrogenase (KGDH) inhibitor, (S)-2-[(2,6-dichlorobenzoyl) amino] succinic acid (AA6), in an orthotopic mouse model of breast cancer 4T1 and in other human breast cancer cell lines. In all conditions, AA6 altered Krebs cycle causing intracellular α-ketoglutarate (α-KG) accumulation. Consequently, the activity of the α-KG-dependent epigenetic enzymes, including the DNA demethylation ten-eleven translocation translocation hydroxylases (TETs), was increased. In mice, AA6 injection reduced metastasis formation and increased 5hmC levels in primary tumours. Moreover, in vitro and in vivo treatment with AA6 determined an α-KG accumulation paralleled by an enhanced production of nitric oxide (NO). This epigenetically remodelled metabolic environment efficiently counteracted the initiating steps of tumour invasion inhibiting the epithelial-to-mesenchymal transition (EMT). Mechanistically, AA6 treatment could be linked to upregulation of the NO-sensitive anti-metastatic miRNA 200 family and down-modulation of EMT-associated transcription factor Zeb1 and its CtBP1 cofactor. This scenario led to a decrease of the matrix metalloproteinase 3 (MMP3) and to an impairment of 4T1 aggressiveness. Overall, our data suggest that AA6 determines an α-KG-dependent epigenetic regulation of the TET–miR200–Zeb1/CtBP1–MMP3 axis providing an anti-metastatic effect in a mouse model of breast cancer-associated metastasis.
Background
Musclin is an activity‐stimulated and cardioprotective myokine that attenuates pathological cardiac remodeling. Musclin deficiency, in turn, results in reduced physical endurance. The aim of this study was to assess the prognostic value of circulating musclin as a novel, putative biomarker to identify patients undergoing transcatheter aortic valve implantation (TAVI) who are at a higher risk of death.
Methods and Results
In this study, we measured systemic musclin levels in 368 patients undergoing TAVI who were at low to intermediate clinical risk (median EuroSCORE [European System for Cardiac Operative Risk Evaluation] II: 3.5; quartile 1–quartile, 2.2%–5.3%), whereby 209 (56.8%) patients were at low and 159 (43.2%) were at intermediate risk. Median preprocedural musclin levels were 2.7 ng/mL (quartile 1–quartile 3, 1.5–4.6 ng/mL). Musclin levels were dichotomized in low (<2.862 ng/mL, n=199 [54.1%]) or high (≥ 2.862 ng/mL, n=169 [45.9%]) groups using cutoff values determined by classification and regression tree analysis. The primary end point was 1‐year overall survival. Patients with low circulating musclin levels exhibited a significantly higher prevalence of frailty, low albumin values, hypertension, and history of stroke as well as higher N‐terminal pro‐B‐type natriuretic peptide. Low musclin levels significantly predicted risk of death in univariable (hazard ratio, 1.81; 95% CI, 1.00–3.53 [P=0.049]) and multivariable (adjusted hazard ratio, 2.45; 95% CI, 1.06–5.69 [P=0.037]) Cox regression analyses. Additionally, low musclin levels in combination with conventional EuroSCORE II suggested improved risk stratification in patients undergoing TAVI who were at low to intermediate clinical risk into subgroups with reduced 1‐year survival rates by log‐rank test (P for trend=0.003).
Conclusions
Circulating musclin is an independent predictor of 1‐year overall survival in patients undergoing TAVI. Combined with EuroSCORE II, circulating musclin might help to improve prediction of mortality in patients undergoing TAVI who are at low to intermediate clinical risk.
Background: Patients with chronic kidney disease (CKD) are at high risk of myocardial infarction. Cardiac troponins are the biomarkers of choice for the diagnosis of acute myocardial infarction (AMI) without ST‐segment elevation (NSTE). In patients with CKD, troponin levels are often chronically elevated, which reduces their diagnostic utility when NSTE‐AMI is suspected. The aim of this study was to derive a diagnostic algorithm for serial troponin measurements in patients with CKD and suspected NSTE‐AMI.
Methods and Results: Two cohorts, 1494 patients from a prospective cohort study with high‐sensitivity troponin I (hs‐cTnI) measurements and 7059 cases from a clinical registry with high‐sensitivity troponin T (hs‐cTnT ) measurements, were analyzed. The prospective cohort comprised 280 CKD patients (estimated glomerular filtration rate <60 mL/min/1.73 m2). The registry data set contained 1581 CKD patients. In both cohorts, CKD patients were more likely to have adjudicated NSTE‐AMI than non‐CKD patients. The specificities of hs‐cTnI and hs‐cTnT to detect NSTE‐AMI were reduced with CKD (0.82 versus 0.91 for hs‐cTnI and 0.26 versus 0.73 for hs‐cTnT) but could be restored by applying optimized cutoffs to either the first or a second measurement after 3 hours. The best diagnostic performance was achieved with an algorithm that incorporates serial measurements and rules in or out AMI in 69% (hs‐cTnI) and 55% (hs‐cTnT) of CKD patients.
Conclusions: The diagnostic performance of high‐sensitivity cardiac troponins in patients with CKD with suspected NSTE‐AMI is improved by use of an algorithm based on admission troponin and dynamic changes in troponin concentration.